Indian Journal of Pharmacology Home 

EDUCATION FORUM
[View FULLTEXT] [Download PDF]
Year : 2004  |  Volume : 36  |  Issue : 3  |  Page : 140--147

Intranasal delivery: An approach to bypass the blood brain barrier

S Talegaonkar, PR Mishra 
 Department of Pharmaceutics, Jamia Hamdard, New Delhi -110062, India

Correspondence Address:
S Talegaonkar
Department of Pharmaceutics, Jamia Hamdard, New Delhi -110062
India

The blood brain barrier (BBB) represents one of the strictest barriers of in vivo therapeutic drug delivery. The barrier is defined by restricted exchange of hydrophilic compounds, small proteins and charged molecules between the plasma and central nervous system (CNS). For decades, the BBB has prevented the use of many therapeutic agents for treating Alzheimer«SQ»s disease, stroke, brain tumor, head injury, spinal cord injury, depression, anxiety and other CNS disorders. Different attempts were made to deliver the drug across the BBB such as modification of therapeutic agents, altering the barrier integrity, carrier-mediated transport, invasive techniques, etc. However, opening the barrier by such means allows entry of toxins and undesirable molecules to the CNS, resulting in potentially significant damage. An attempt to overcome the barrier in vivo has focused on bypassing the BBB by using a novel, practical, simple and non-invasive approach i.e. intranasal delivery. This method works because of the unique connection which the olfactory and trigeminal nerves (involved in sensing odors and chemicals) provide between the brain and external environments. The olfactory epithelium acting as a gateway for substances entering the CNS and peripheral circulation is well known. Also, it is common knowledge that viral infections such as common cold, smallpox, measles, and chicken pox take place through the nasopharynx. The neural connections between the nasal mucosa and the brain provide a unique pathway for the non-invasive delivery of therapeutic agents to the CNS. This pathway also allows drugs which do not cross the BBB to enter the CNS and it eliminates the need for systemic delivery and thereby reducing unwanted systemic side effects. Intranasal delivery does not require any modification of therapeutic agents and does not require that drugs be coupled with any carrier. A wide variety of therapeutic agents, including both small molecules and macromolecules can be rapidly delivered to the CNS using this method. The present review discusses the various applications, advantages and limitations of this novel approach.


How to cite this article:
Talegaonkar S, Mishra P R. Intranasal delivery: An approach to bypass the blood brain barrier.Indian J Pharmacol 2004;36:140-147


How to cite this URL:
Talegaonkar S, Mishra P R. Intranasal delivery: An approach to bypass the blood brain barrier. Indian J Pharmacol [serial online] 2004 [cited 2019 Nov 22 ];36:140-147
Available from: http://www.ijp-online.com/article.asp?issn=0253-7613;year=2004;volume=36;issue=3;spage=140;epage=147;aulast=Talegaonkar;type=0